{"id":122710,"date":"2026-01-13T11:12:00","date_gmt":"2026-01-13T14:12:00","guid":{"rendered":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/citeline-risklick-partnership-creates-smarter-protocols-from-design-to-optimization\/"},"modified":"2026-01-13T11:12:00","modified_gmt":"2026-01-13T14:12:00","slug":"citeline-risklick-partnership-creates-smarter-protocols-from-design-to-optimization","status":"publish","type":"post","link":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/citeline-risklick-partnership-creates-smarter-protocols-from-design-to-optimization\/","title":{"rendered":"Citeline-Risklick Partnership Creates Smarter Protocols, from Design to Optimization"},"content":{"rendered":"

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) — Citeline, a leader in clinical solutions for the life sciences industry, and Risklick, a Swiss-based company specializing in AI-driven solutions for clinical trial protocol development, have partnered to develop a holistic solution that spans protocol design and authoring, operationalization and regulatory disclosure.<\/p>\n

Industry studies reveal that protocol amendments have risen substantially since 2015. Given that a single protocol amendment can cost between $140,000 and $500,000, sponsors are under pressure to design near-foolproof protocols.<\/p>\n

Together, Risklick and Citeline deliver an integrated, intelligent protocol development experience that combines smart authoring with AI-powered optimization, directly in the workflow. The result is optimally designed, patient-centered protocols that reduce risk, accelerate timelines and improve enrollment outcomes.<\/p>\n

With deep expertise in protocol component design, Citeline leverages its robust data and AI for evidence-based optimization of protocol endpoints and inclusion\/exclusion (I\/E) criteria. In addition, its AI models drawing from successful trials, biomarkers, real-world patient data, and proprietary sponsor data fine-tune operational forecasting and planning.<\/p>\n

By embedding our best-in-class data directly into a digitized workflow, we are transforming protocol design from a manual hurdle into a high-speed, AI-driven engine that allows sponsors to move from concept to execution faster than ever before, says Suzanne Caruso, General Manager, Citeline Strategic Intelligence, Clinical & Regulatory. <\/p>\n

Risklick, bringing to the table extensive protocol design and authoring workflow expertise and a purpose-built AI platform, has digitized the entire protocol development process. Its AI assistant focuses on early clinical trial design and literature analysis, based on a user-defined knowledge base.<\/p>\n

“Our mission is to enable the pharmaceutical industry to design a clinical study in <\/strong>just one day, says Dr. Poorya Amini, Founder & CEO, Risklick. This partnership with Citeline is a key step toward making that vision a reality, by bringing together an interoperable solution that spans protocol design, operationalization and regulatory disclosure to create a fully connected digital trial ecosystem.”<\/p>\n

The two companies are digitally transforming protocol development and enhancing data-driven clinical trial design and operations. Their solution combines insights and workflow to improve protocol quality, empowering sponsors to build more predictable trials.<\/p>\n

About Citeline <\/strong>
Citeline, a Norstella<\/a> company, powers a full suite of complementary business intelligence offerings to meet the evolving needs of life science professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-focused solutions and services deliver and analyze data used to drive clinical, commercial, and regulatory-related decisions and create real-world opportunities for growth.<\/p>\n

Citelines global teams of analysts, journalists, and consultants keep their fingers on the pulse of the pharmaceutical, biomedical and medtech industries, covering all with expert insights: key diseases, clinical trials, drug R&D and approvals, market forecasts, and more. For more information on one of the worlds most trusted health science partners, visit Citeline<\/u><\/a> and follow on LinkedIn<\/a> and X<\/a> (Twitter).<\/p>\n

About Risklick
<\/strong>Risklick is a Swiss-based company specializing in AI-driven solutions for clinical trial protocol development. The company partners with global pharmaceutical and biotech organizations to accelerate innovation by providing advanced tools for protocol design, data-driven study planning, and operational efficiency. Risklicks flagship platform, Protocol AI, empowers clinical teams to streamline processes and bring new therapies to patients faster. For more information, visit Risklick<\/a> and follow on LinkedIn<\/a>.<\/p>\n

Citeline PR contact:<\/strong>
Diffusion PR for Citeline
citeline@diffusionpr.com<\/u><\/a>
(213) 318-4500 <\/p>\n

Photos accompanying this announcement are available at<\/p>\n

https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/b77ff161-d84c-46f2-a2d3-abaf9e187dbd<\/a><\/p>\n

https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/590b144d-7883-4a17-b869-c52715219df3<\/a><\/p>\n

\"\"
\"\"
\n\"Primary<\/a><\/p>\n

\n
\n
\n
\n
Suzanne Caruso<\/h5>\n<\/div>\n
<\/a><\/div>\n

\n

\n
Suzanne Caruso, Citeline<\/h5>\n<\/div>\n
\n
Poorya Amini<\/h5>\n<\/div>\n
<\/a><\/div>\n

\n

\n
Dr. Poorya Amini, Risklick<\/h5>\n<\/div>\n<\/div>\n<\/div>\n

A OESP<\/b> nao e(sao) responsavel(is) por erros, incorrecoes, atrasos ou quaisquer decisoes tomadas por seus clientes com base nos Conteudos ora disponibilizados, bem como tais Conteudos nao representam a opiniao da OESP<\/b> e sao de inteira responsabilidade da GlobeNewswire<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) — Citeline, a leader in clinical solutions for the life sciences industry, and Risklick, a Swiss-based company sp","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[34],"tags":[],"class_list":["post-122710","post","type-post","status-publish","format-standard","hentry","category-releases-geral"],"acf":[],"_links":{"self":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts\/122710","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/comments?post=122710"}],"version-history":[{"count":0,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts\/122710\/revisions"}],"wp:attachment":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/media?parent=122710"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/categories?post=122710"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/tags?post=122710"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}